Premium
Effects of exendin‐4 on islets from type 2 diabetes patients
Author(s) -
Lupi R.,
Mancarella R.,
Del Guerra S.,
Bugliani M.,
Del Prato S.,
Boggi U.,
Mosca F.,
Filipponi F.,
Marchetti P.
Publication year - 2008
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/j.1463-1326.2007.00838.x
Subject(s) - exenatide , islet , type 2 diabetes , endocrinology , pancreatic islets , medicine , secretion , dipeptidyl peptidase , beta cell , glucagon like peptide 1 , insulin , dipeptidyl peptidase 4 , diabetes mellitus , chemistry , biochemistry , enzyme
Exendin‐4 is a dipeptidyl peptidase IV (DPP‐IV)‐resistant glucagon‐like peptide1 (GLP‐1) mimetic and its synthetic counterpart, exenatide, is being used in the therapy of type 2 diabetes (T2DM). No information, however, is currently available as for the direct action of exendin‐4 on human T2DM islets. In the present study, we exposed pancreatic islets prepared from non‐diabetic and T2DM subjects to exendin‐4 for 48 h and found that the compound had several, direct beneficial actions on insulin secretion and the expression of genes involved in beta‐cell function and differentiation.